Braincool
BrainCool is a Swedish medical device company focused on patient temperature management systems used in acute care and other hospital settings. Its product platform includes BrainCool/IQool, RhinoChill, and Cooral systems, each supported by related consumables and managed through separate subsidiaries.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueReusable medical cooling devices sold for specific acute-care and oncology indications.
Single-use cooling pads and related items used with installed systems.
Partner-led sales of systems through distributors such as ZOLL in multiple markets.
Customers
BrainCool sells primarily to hospitals, emergency care providers, and healthcare systems that treat stroke, cardiac arrest, fever management, and chemotherapy-related indications. It also serves distributors and channel partners that market and place the systems in approved markets. Demand is driven by clinical need, regulatory approval, installed-base expansion, and recurring consumable usage.
Buy BrainCool/IQool systems for in-hospital temperature management in neurological and cardiac indications.
Use RhinoChill-type solutions for rapid cooling in pre-hospital or emergency settings.
Use Cooral-related cooling solutions to reduce side effects of chemotherapy.
Purchase and market systems in defined territories, expanding reach and regulatory coverage.
Strategy
BrainCool’s strategy is to expand its installed base through distributor partnerships while increasing recurring consumable sales from each deployed system. It also relies on clinical evidence, regulatory approvals, and product-specific commercialization to open new indications and new countries. The business is structured to scale through outsourced manufacturing and channel partners rather than heavy internal production capacity.
Channel partners extend market reach without building a large direct sales force.
Each system sold can generate recurring demand for pads and other single-use items.
Medical adoption depends on evidence generation and country-by-country approvals.
Geography
BrainCool is headquartered in Sweden and sells through a distributor-led model across Europe, the U.S., and selected Asian markets. The ZOLL agreement covers the U.S., Germany, Switzerland, and Austria, while additional Asian markets such as Thailand, Singapore, Indonesia, the Philippines, Malaysia, Taiwan, Pakistan, and Japan are being developed as approvals are obtained. Geography matters because market access depends on local regulatory clearance and distributor execution.
Risks
BrainCool faces regulatory, clinical, and commercialization risk because each market and indication requires evidence, approvals, and distributor execution before sales can scale. As a medical device company with outsourced manufacturing and a consumables-linked model, it is also exposed to supplier dependence, product adoption risk, and demand variability tied to installed-base growth. Broader medtech risks include reimbursement pressure, competition from alternative therapies, and execution risk in international expansion.
- Regulatory approval delaysImpact: HighLikelihood: Medium
Deliveries in several markets cannot begin until local approvals are obtained.
Exposure: Asia expansion and Japan
- Clinical adoption and evidence riskImpact: HighLikelihood: Medium
Hospital buyers rely on clinical studies and proven outcomes before broad adoption.
Exposure: All product lines
- Distributor concentrationImpact: MediumLikelihood: Medium
A significant portion of commercialization depends on partners such as ZOLL.
Exposure: U.S. and selected international markets
- Supplier and manufacturing dependenceImpact: MediumLikelihood: Low
Production is subcontracted, so quality, lead times, and supply continuity matter.
Exposure: All products
Accounting
Judgemental itemsLong product-development cycles mean amortization periods and impairment assumptions can materially affect earnings.
Impact: Intangible assets and operating profit
System deliveries and recurring consumables may be recognized at different points in time.
Impact: Quarterly revenue mix and gross margin
Management notes stronger end-of-year demand, which can distort quarter-to-quarter comparability.
Impact: Reported quarterly sales and margins
The company has significant tax losses, but deferred tax assets are recognized cautiously until future profits are probable.
Impact: Balance sheet and tax expense
Similar listed companies
Publicly listed companies with a comparable business focus.
Gentherm Inc
THRM · Motor Vehicle Parts & Accessories
Sleep Cycle
SLEEP · Technology
Sleep Cycle is a technology company focused on improving global health by enhancing sleep quality through advanced sleep analysis and personalized insights.
Brainsway Ltd.
BWAY · Surgical & Medical Instruments & Apparatus
Bravida Holding
BRAV · Industrials
Bravida Holding AB is a Nordic leader in providing comprehensive technical solutions for buildings and facilities.
Vycor Medical Inc
VYCO · Surgical & Medical Instruments & Apparatus
electroCore, Inc.
ECOR · Electromedical & Electrotherapeutic Apparatus
Last updated: 24/09/2026